Patent Number: 8,871,219

Title: Recombinant vectors based on the modified vaccinia ankara virus (MVA) as preventive and therapeutic vaccines against AIDS

Abstract: Recombinant vectors which are based on the Modified Ankara Virus (MVA) as preventive and therapeutic vaccines against AIDS. The recombinant viruses contain sequences which are inserted at an MVA insertion site and enable simultaneous expression of antigens, a HIV-1 Env protein consisting of a gp120 protein lacking sequences corresponding to protein gp 41 and a chimeric fusion protein of Gag, Pol and Nef. These viruses are stable and can trigger immune responses against a large variety of antigens. Viruses having a chimeric protein from HIV-1 are suitable for the preparation of vaccines against AIDS.

Inventors: Heeney; Jonathan (Rijswijk, NL), Mooij; Petra (Rijswijk, NL), Gomez Rodriguez; Carmen Elena (Madrid, ES), Najera Garcia; Jose Luis (Madrid, ES), Jimenez Tentor; Victoria (Madrid, ES), Esteban Rodriguez; Mariano (Madrid, ES)

Assignee: Consejo Superior de Investigaciones Cientificas

International Classification: C12N 15/863 (20060101); A61K 39/21 (20060101); A61K 31/7088 (20060101); C12N 15/63 (20060101)

Expiration Date: 2018-10-28 0:00:00